Frizziero Luisa, Calciati Andrea, Torresin Tommaso, Midena Giulia, Parrozzani Raffaele, Pilotto Elisabetta, Midena Edoardo
Department of Neuroscience-Ophthalmology, University of Padova, 35128 Padova, Italy.
IRCCS-Fondazione Bietti, 00120 Rome, Italy.
J Pers Med. 2021 May 13;11(5):405. doi: 10.3390/jpm11050405.
The aim of this study was to evaluate the long-term efficacy and safety of 577-nm subthreshold micropulse laser (SMPL) treatment in a large population of patients affected by mild diabetic macular edema (DME) in a real-life setting. We retrospectively evaluated 134 eyes affected by previously untreated center-involving mild DME, and treated with 577-nm SMPL, using fixed parameters. Retreatment was performed at 3 months, in case of persistent retinal thickening. Optical coherence tomography (OCT), along with short and near-infrared fundus autofluorescence, were used to confirm long-term safety. At the end of at least one year follow-up, a significant improvement in visual acuity was documented, compared to baseline (77.3 ± 4.5 and 79.4 ± 4.4 ETDRS score at baseline and at final follow-up, respectively), as well as a reduction in the mean retinal thickness of the thickest ETDRS macular sector at baseline. A reduction in the central retinal thickness and the mean thickness of the nine ETDRS sectors was also found, without reaching statistical significance. No patients required intravitreal injections. No adverse effects were detected. This study suggests that 577-nm SMPL is a safe and repeatable treatment for mild DME that may be applied to real-life clinical settings using fixed parameters and protocols.
本研究的目的是在现实环境中，评估577纳米阈下微脉冲激光（SMPL）治疗大量轻度糖尿病性黄斑水肿（DME）患者的长期疗效和安全性。我们回顾性评估了134只先前未经治疗的累及中心凹的轻度DME患眼，使用固定参数，采用577纳米SMPL进行治疗。若出现持续性视网膜增厚，则在3个月时进行再次治疗。光学相干断层扫描（OCT）以及短波和近红外眼底自发荧光用于确认长期安全性。在至少一年的随访结束时，与基线相比，视力有显著改善（基线时和最终随访时的ETDRS视力评分分别为77.3±4.5和79.4±4.4），并且基线时最厚的ETDRS黄斑区的平均视网膜厚度有所降低。还发现中心视网膜厚度和九个ETDRS区的平均厚度有所降低，但未达到统计学意义。没有患者需要玻璃体腔注射。未检测到不良反应。本研究表明，577纳米SMPL是一种安全且可重复的轻度DME治疗方法，可使用固定参数和方案应用于现实临床环境。
